Subscription Agency
Exploring and Distributing Knowledge Globally

Pharmaceutical Sciences
Volume 5 Issue 2, 2025
eISSN No.: 2582-8371

Theranostics in Oncology Targeted Imaging and Therapy – A Review

Raghavendra Kumar Gunda*[*], Suresh Kumar JN, Narala Venkata Gouthami, Thikka Kanakaiah, Syed Gouse Baji, Yarlagadda Anuhya, Gotru Sujith
Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences (Autonomous), Narasaraopet, Palnadu (Dt), Andhra Pradesh, India-522601.

***Corresponding Author**
Email Id: raghav.gunda@gmail.com

ABSTRACT

Theranostics is an innovative and fast-developing approach in oncology that merges diagnostic imaging with targeted therapy in a single framework. By employing molecular agents such as antibodies, peptides, and nanoparticles, this strategy facilitates accurate tumor detection, site-specific drug delivery, and continuous monitoring of treatment outcomes. Personalized theranostic applications have already demonstrated considerable success in managing conditions like prostate cancer and neuroendocrine tumors. The approach provides key advantages, including enhanced specificity, minimized systemic toxicity, and patient-tailored treatment. Ongoing progress in molecular imaging, nanotechnology, and radiopharmaceutical design is anticipated to broaden the scope of theranostics across diverse malignancies, reinforcing its role as a cornerstone of precision oncology.

Keywords: *Theranostics, tumour detection, neuroendocrine tumor, molecular imaging, Nanotechnology.*

INTRODUCTION

Cancer remains a major global health challenge and one of the primary causes of mortality, emphasizing the urgent need for innovative approaches in detection, treatment, and therapeutic monitoring. Conventional practices often separate diagnostic procedures from therapy, which may result in treatment delays, unnecessary exposure, or increased toxicity. Theragnostics a concept derived from the integration of therapy and diagnostics addresses this limitation by combining molecular imaging with targeted treatment within a single clinical platform. This dual-purpose strategy relies on disease-specific biomarkers that enable clinicians to identify malignant cells, deliver therapeutic payloads with precision, and track treatment response simultaneously. In oncology, targeted imaging agents such as antibodies, nanoparticles, or radioisotope labelled compounds allow for highly sensitive tumour visualization. When conjugated with therapeutic moieties including radionuclides, chemotherapeutic drugs, or photothermal agents the same carriers can be transformed into treatment tools. Such dual functionality supports the principles of personalized medicine, ensuring that patients receive optimized care with fewer side effects and better clinical outcomes [1].

Theranostics refers to the integration of diagnostic tools with targeted treatment strategies to manage cancer more effectively. In this approach, diagnostic agents are first employed to identify specific biological or molecular features of tumor cells. These findings are then used to guide and customize treatment for each patient. By linking diagnosis and therapy, theranostics enables oncologists to design individualized treatment plans, maximize therapeutic efficacy, and minimize unwanted side effects. This personalized methodology is increasingly being recognized as a powerful tool for improving cancer care [2].

Targeted Imaging in Theranostics

Targeted imaging is a cornerstone of theranostics, allowing clinicians to visualize and monitor specific characteristics of cancer cells. This is accomplished using specialized imaging agents that selectively bind to tumor cells, providing precise information about disease presence and progression. Common imaging techniques employed in theranostics include:

1) Positron Emission Tomography (PET): Utilizes small amounts of radioactive tracers to highlight cancerous tissues.
2) Single Photon Emission Computed Tomography (SPECT): Uses gamma radiation to produce detailed images of tumor regions.
3) Magnetic Resonance Imaging (MRI): Employs strong magnetic fields and radio waves to generate high-resolution images of tumors [3-4].

By leveraging these modalities, targeted imaging not only aids in accurate diagnosis but also supports treatment planning and ongoing monitoring, forming an essential component of personalized oncology.

Targeted Therapy in Theranostics

Targeted therapy is a fundamental element of theranostics, where treatment strategies are customized according to diagnostic findings. This approach allows clinicians to select therapies that specifically address the molecular or cellular features of a patient's cancer, thereby improving efficacy and reducing adverse effects. Some commonly employed targeted therapeutic strategies include:

1) Nanoparticles: Ultra-small particles engineered to deliver drugs directly to cancer cells, minimizing impact on healthy tissues.
2) Monoclonal antibodies: Proteins designed to recognize and bind selectively to tumor antigens, carrying therapeutic agents to the site of disease.
3) Small molecule inhibitors: Compounds that interfere with specific signaling pathways critical to cancer cell growth and survival [5].

By integrating these therapies with diagnostic imaging, theranostics ensures precise, individualized treatment, enhancing outcomes and supporting the principles of personalized medicine.

Theranostics in Oncology

Theranostics is revolutionizing cancer care by combining targeted imaging with therapy to deliver personalized treatment strategies. This integrated approach enables clinicians to diagnose tumors more accurately, monitor disease progression in real time, and administer treatments tailored to each patient's unique molecular profile. Recent advancements have demonstrated significant benefits in various cancers, including prostate cancer and neuroendocrine tumors. By merging diagnostic and therapeutic functionalities, theranostics enhances treatment precision, minimizes collateral damage to healthy tissues, and supports individualized patient care. As technology continues to advance, the applications of theranostics are expected to expand, further solidifying its role as a key tool in modern precision oncology.

Pharmaceutical Sciences
Volume 5 Issue 2, 2025
eISSN No.: 2582-8371

The integration of diagnostic imaging and targeted therapy in theranostics provides several important advantages in cancer management:

1) Enhanced Diagnostic Accuracy: Targeted imaging allows clinicians to detect tumors more precisely and monitor disease progression effectively.
2) Personalized Treatment: Therapeutic interventions are tailored to the individual patient's molecular and cellular profile, improving treatment relevance.
3) Improved Clinical Outcomes: Personalized strategies can increase the effectiveness of cancer management, leading to better response rates.
4) Reduced Side Effects: By focusing treatment specifically on tumor cells, theranostics minimizes damage to healthy tissues and lowers the risk of adverse reactions [6].

These benefits collectively support the implementation of theranostics as a vital component of precision oncology, offering more effective and patient-centered care.

Theranostic Nanoparticles in Cancer Management

Theranostic nanoparticles represent a promising advancement in personalized cancer therapy by combining diagnostic and therapeutic functions within a single platform. These multifunctional systems enable simultaneous tumor detection, treatment delivery, and monitoring of therapeutic response, thereby improving precision and efficiency. Recent research has explored diverse strategies for cancer management using theranostic nanoparticles. Approaches include nucleic acid delivery for gene modulation, encapsulation of chemotherapeutic agents, hyperthermia via photothermal methods, photodynamic therapy with light-activated compounds, and radiation-based interventions. These therapeutic methods are often integrated with imaging technologies that allow real-time visualization of drug distribution, treatment response, and disease progression. By offering both diagnostic and therapeutic capabilities, theranostic nanoparticles serve as powerful tools to enhance treatment outcomes and support the goals of precision oncology [7-8].

Molecular Imaging in Cancer Theranostics

Molecular imaging plays a critical role in cancer theranostics by allowing clinicians to observe biological processes within the living body in real time. Unlike traditional *in vitro* diagnostic methods such as genomic, transcriptomic, proteomic, or metabolomic analyses, molecular imaging provides direct visualization of cellular and molecular activities in their natural physiological context. A wide array of imaging modalities is employed in molecular imaging, including molecular magnetic resonance imaging (mMRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), photoacoustic imaging (PAI), and optical imaging (OI). Each technique offers unique advantages; some excel in sensitivity, while others provide higher spatial resolution or the ability to monitor multiple molecular targets simultaneously. Molecular imaging facilitates early cancer detection, evaluates the pharmacokinetics and pharmacodynamics of novel therapies, and enables real-time monitoring of treatment response often identifying therapeutic effects before observable anatomical changes occur. This capability makes molecular imaging a cornerstone of modern cancer theranostics, supporting timely interventions and personalized treatment strategies [9-10].



Figure 1: Cancer Treatment strategies with Molecular Imaging Theranostics

Imaging-Guided Cancer Therapy

Imaging-guided cancer therapy uses advanced imaging techniques such as X-rays, CT, MRI, and ultrasound to navigate therapeutic instruments to precise tumor locations. Over the past two decades, innovations in imaging systems and tracking technologies have enabled minimally invasive interventions, reducing the need for traditional open surgeries. These techniques allow clinicians to combine preoperative static imaging (e.g., CT or MRI scans) with real-time modalities such as ultrasound, creating an accurate spatial map of the treatment site. By overlaying instrument positions onto patient anatomy, practitioners can perform precise interventions with enhanced safety and effectiveness [11-12].

Common image-guided oncological procedures include:
Radiofrequency ablation (RFA): Uses localized heating to destroy tumor tissue.

Microwave ablation: Employs electromagnetic waves to rapidly heat and ablate cancer cells.

Cryoablation: Freezes tumors for localized destruction [13].

Chemoembolization: Delivers chemotherapeutic agents directly into tumor vasculature. Selective Internal Radiation Therapy (SIRT): Administers radioactive microspheres to inoperable tumors, often in the liver. Dose painting: Uses functional imaging to deliver non-uniform radiation doses, targeting resistant tumor regions. By integrating precise imaging with therapeutic interventions, these techniques improve treatment accuracy, reduce patient recovery time, and minimize complications.

Theranostic Platforms

Various theranostic platforms have been developed to combine diagnostic imaging and therapeutic interventions, enhancing precision and safety in cancer treatment. These platforms leverage external triggers such as light, magnetism, and sound to control drug delivery and therapeutic actions with high spatial and temporal accuracy.

Pharmaceutical Sciences
Volume 5 Issue 2, 2025
eISSN No.: 2582-8371

Light-Responsive Platforms:

Light-based strategies allow controlled activation of therapeutic agents at the tumor site. Examples include:

Photodynamic therapy (PDT): Uses photosensitizers activated by specific light wavelengths in the presence of oxygen to produce reactive oxygen species, killing tumor cells.

Photothermal therapy (PTT): Converts light energy into localized heat to destroy cancerous tissue while sparing nearby healthy cells.

Phototriggered chemotherapy: Drug carriers release therapeutic molecules upon light exposure, enabling precise dosing. Light-based optical imaging techniques, including fluorescence, bioluminescence, phosphorescence, Raman scattering, and photoacoustic imaging, are used to track tumors and treatment response in real time [14].

Magnetic Platforms:

Magnetic resonance imaging (MRI) provides high-resolution imaging, often enhanced with contrast agents like superparamagnetic iron oxide nanoparticles (SPIOs). Beyond imaging, magnetic nanoparticles can generate heat under alternating magnetic fields for hyperthermia treatment, act as drug carriers, or facilitate cell tracking and separation [15].

Ultrasound-Based Platforms:

Ultrasound technologies offer both diagnostic and therapeutic applications. Contrast-enhanced ultrasound improves tumor visualization using microbubbles, while high-intensity focused ultrasound (HIFU) delivers energy to ablate tissue. Ultrasound-responsive nanoparticles can release therapeutic payloads in response to acoustic energy, combining imaging and treatment in a single platform [16-17]. These multifunctional platforms exemplify how integrating physical triggers with nanotechnology enables precise, controlled, and personalized cancer therapy.

Multifunctional Platforms for Cancer Theranostics

Modern theranostic platforms are designed to integrate multiple therapeutic modalities, such as chemotherapy combined with hyperthermia, to exploit synergistic effects and improve treatment efficacy. These multifunctional systems allow simultaneous monitoring and therapy, offering a more comprehensive approach to cancer management.

CHALLENGES AND FUTURE PERSPECTIVES

Personalized oncology focuses on delivering patient-specific, evidence-based care to ensure that treatments reach the right patient at the right time. Theranostic biomarkers, obtained from tissue, blood, urine, or imaging, play a crucial role in guiding therapy but require rigorous validation for clinical reliability [18]**.** Advances in genomics and other omics technologies have generated vast datasets that facilitate the discovery of new molecular biomarkers and provide insights into disease mechanisms. By integrating *in vitro* molecular diagnostics with whole-body molecular imaging, clinicians can achieve earlier predictions, more accurate diagnoses, and improved monitoring of therapeutic response. Although nanoplatforms show great potential in cancer theranostics, their clinical translation faces several obstacles:

Scale-up and reproducibility: Complex nanostructures are challenging to reproduce consistently at a large scale while maintaining sterility [19].

Integration of imaging and therapy: Differences in pharmacokinetics and tumor targeting between imaging and therapeutic components can limit synergy.

Regulatory challenges: Clear guidance for nanotheranostics from agencies like the FDA is still lacking [20].

Nanotoxicity: Potential cytotoxic, genotoxic, or immunotoxic effects require careful risk assessment.

Economic considerations: Commercial adoption of advanced theranostic formulations is still in progress. Despite these challenges, the convergence of diagnostic and therapeutic capabilities into single platforms continues to drive research and clinical development, with the goal of creating more effective and personalized cancer treatments [21].

CONCLUSION

A comprehensive understanding of cancer biology, combined with the identification of definitive biomarkers, is essential for advancing theranostic strategies. The development of ultrasensitive measurement tools, early high-resolution tumor visualization, and predictive methods for therapeutic response allows clinicians to intervene before anatomical changes occur. Molecularly targeted treatments, particularly nanotherapeutics, offer significant promise in improving precision and reducing systemic toxicity. By integrating these approaches into a unified theranostic framework, healthcare providers can deliver personalized, evidence-based care that addresses unmet clinical needs and enhances the overall effectiveness of cancer management.

REFERENCES

1) Wu Y, Shang J, Zhang X, Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review. J Nanobiotechnol. 2024;22:783.
2) Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoğlu K, A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiology: Imaging Cancer. 2023;5(4):220157.
3) Palihati M, Das JP, Yeh R, Capaccione K. Emerging PET imaging agents and targeted radioligand therapy: a review of clinical applications and trials. Tomography. 2025;11(8):83.
4) Bonlawar J, Setia A, Challa RR, Vallamkonda B, Mehata AK, Vaishali, Viswanadh MK, Muthu MS. Targeted Nanotheranostics: Integration of Preclinical MRI and CT in the molecular imaging and therapy of advanced diseases. Nanotheranostics. 2024;8(3):401–426.
5) Mao Y, Xie J, Yang F, Advances and prospects of precision nanomedicine in personalized tumor theranostics. Front Cell Dev Biol. 2024 Dec 5;12:1514399.
6) Pratihar S, Bhagavath KK, Govindaraju T. Small molecules and conjugates as theranostic agents. RSC Chem Biol. 2023 Sep;4:826–849.
7) Rui L, Zhou X, Wang X, Advances and innovations in ultrasound-based tumor theranostics. Pharmaceutics. 2025;14(6):1282.
8) Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024;14(6):2367–2378.
9) Baum RP. Theranostics in nuclear medicine: Application in oncology. Clin Trans Imaging. 2016;53–56.
10) Fernandes DA. Liposomes for cancer theranostics. Pharmaceutics. 2023;15(10):2448–2450.

11) Yang Y, Zhou X, Wang X, A review of combined imaging and therapeutic applications of magnetic nanomaterials. Front Chem. 2025;13:1595376.
12) Parthasarathy N, Sundaramurthi D, Ravichandran R, Recent progress in multifunctional theranostic inorganic nanoparticles for cancer therapy. J Nanobiotechnol. 2025;23(1):1–15.
13) Li G, Zhang Y, Wang X, Advances in smart nanotechnology-supported photodynamic therapy for cancer treatment. Front Bioeng Biotechnol. 2024;12:1514890.
14) Burkett BJ, MacLennan S, Dierckx R, A review of theranostics: perspectives on emerging approaches and clinical applications. Radiology: Imaging Cancer. 2023;5(2):220157.
15) Bai JW, Zhou X, Zhang Y, Molecular and functional imaging in cancer-targeted therapy. Signal Transduct Target Theranostics. 2023;8(1):1–15.
16) Brock KK, MacLennan S, Dierckx R, Imaging in interventional radiology: 2043 and beyond. Radiology. 2023;307(1):1-12.
17) Criss CR, Bai JW, Zhou X, Recent advances in image-guided locoregional therapies for hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1–15.
18) Cai Y, Zhou X, Wang X, Phototherapy in cancer treatment: strategies and challenges. Signal Transduct Target Ther. 2025;10(1):1–15.
19) Karthikeyan L, Gawne PJ, Mahmud MM, Multifunctional theranostic nanomedicines for cancer treatment: A recent progress and challenges. Sci Adv Mater. 2023;15(1):1–17.
20) Kashyap BK, Mahmud MM, Gawne PJ, Smart nanomaterials in cancer theranostics: Challenges and future directions. Nanomedicine. 2023;18(5):1–15.
21) Anitha K, Rani S, Suresh P, Advancing cancer theranostics through biomimetics. Biomaterials Advances. 2024;134:112591.